P&T COMMITTEE MEETING

Agenda January 07, 2020
1:00 p.m. – 5:00 p.m.

303 E. 17th Ave, 11th Floor Conference Rooms (11ABC), Denver, CO 80203

Committee Member Introductions

- Openings/New Appointments
- Vote on New Chair/Vice Chair

Unfinished Business and General Orders

- Approval of minutes from October 08, 2019 P&T meeting
- Update on Anti-Emetics
- Update on Anti-Platelets
- Update on Antipsoriasis – Oral and Non-Oral
- Update on Epinephrine Auto-Injector Products
- Update on Hepatitis C Virus Treatments - Direct-Acting Antivirals
- Update on NSAIDs – Oral and Non-Oral
- Update on Pulmonary Arterial Hypertension (PAH) Agents
  - Endothelial Antagonists
  - Guanylate Cyclase
  - Phosphodiesterase Inhibitors
  - Prostanoids
- Update on Targeted Immune Modulators (TIMs)
- Update on Pancreatic Enzymes
- Update on Non-Biologic Ulcerative Colitis Agents – Oral and Non-Oral
- Update on Mass review drug classes:
  - Anti-Depressants
    - Monoamine Oxidase Inhibitors (MAOIs)
    - Newer Generation
    - Tricyclics (TCAs)
  - Anti-herpetics – Oral and Non-Oral
  - Anti-hyperuricemics
  - Fluoroquinolones, Oral
  - H. Pylori Treatments
  - Hepatitis C – Single-Agent Ribavirin Products
  - Proton Pump Inhibitors
  - Triptans and other Migraine Treatments – Oral and Non-Oral
New Business
- Updates from the Prior Authorization Call Center

Drug Classes Up for Review:
- Review of Antimigraine Agents – Calcitonin Gene-Related Peptide (CGRP) Inhibitors
- Review of Diabetes Management – Insulins
- Review of Glucagon, Self-Administered
- Review of Multiple Sclerosis Agents
- Review of Immune Globulins
- Review of Anti-Parkinson’s Agents
  - Dopa Decarboxylase Inhibitors & Combinations
  - MAO-Bs
  - Dopamine Agonists
  - Other
- Review of Atypical Antipsychotics – removed from Mass Review
- Review of Lithium Agents
- Review of Ophthalmic Allergy Agents
- Review of Ophthalmic Anti-Inflammatories
- Review of Intranasal Rhinitis Agents
- Review of Lipotropics
- Review of Statins & Statin Combinations
- Review of Hemorrhoidal and Related Anorectal Agents
- **Mass review drug classes**:  
  - Bile Salts
  - Growth Hormones
  - Leukotriene Modifiers
  - Neurocognitive Disorder Agents
  - Sedative Hypnotics
    - Non-Benzodiazepine
    - Benzodiazepine
  - Topical Steroids
    - Low Potency
    - Medium Potency
    - High Potency
    - Very High Potency

Each Review will contain:
- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share and FDA updates
- Committee Discussion and Recommendations for each Class

*Mass review drug classes will only include:
- Overview for each Drug Class, including market share and FDA updates
**Upcoming Meeting Date:** Tuesday, April 7, 2020; 1:00 p.m. – 5:00 p.m.

**Presentations:**

Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical information that will be presented for P&T Committee dissemination.

Please contact Brittany Schock, PDL Pharmacist, at 303-866-6371 or by email at brittany.schock@hepf.state.co.us to give advance notice to present at the meeting. Written public comments can be submitted to Jessica Czechowski, Pharmacist Account Executive, jlczechowski@magellanhealth.com (carbon copy Brittany Schock) for review and upon approval will be distributed to all P&T Committee Members. Please provide public comments by January 3, 2020 for oral presentation and dissemination of written comments to the P&T Committee.